Search Protocols under revision. Back New search Go to resultsDiseaseMain groupSolid TumorsProtocol groupEndocrine and Neuroendocrine OncologyDiseaseMalignant PheochromocytomaParagangliomaSubgroupICD10C74.1C75.5MeSHParagangliomaPheochromocytomaSequenceChemotherapyChemo-substanceBelzutifanCabozantinibCyclophosphamideDacarbazineSunitinibVincristineChemo-substanceBelzutifanCabozantinibCyclophosphamideDacarbazineSunitinibVincristineChemo-substanceBelzutifanCabozantinibCyclophosphamideDacarbazineSunitinibVincristineChemo-substanceBelzutifanCabozantinibCyclophosphamideDacarbazineSunitinibVincristineNo. Substances13 RadiotherapySupportive therapySupportive substanceBalanced Crystalloid SolutionDexamethasoneFosaprepitantGranisetronMesnaSupportive substanceBalanced Crystalloid SolutionDexamethasoneFosaprepitantGranisetronMesnaSupportive substanceBalanced Crystalloid SolutionDexamethasoneFosaprepitantGranisetronMesnaSupportive substanceBalanced Crystalloid SolutionDexamethasoneFosaprepitantGranisetronMesnaNo. Substances25Protocol classificationTherapy classificationalternativecurrent standardIntensityStandard doseTherapy indicationFirst lineseveral possibleTherapy phaseTherapy intentionpalliativeRisksAnemia Hb below 8g/dlCardiotoxicityCystitisDiarrheaDyspneaEdemaEmetogenicity (ASCO)Emetogenicity (MASCC/ESMO)Hand-Foot SyndromeHeadacheHepatotoxicityHypertensionHypomagnesemiaHyponatremiaHypothyroidismIncrease AminotransferasesIncrease in lipaseMucositisNeuropathyNeutropeniaQTc Time ExtensionThrombocytopenia below 50 000/µl only studiesPublicationAuthorAsai S Baudin EJimenez CDiseaseFortgeschrittenes oder metastasiertes Phäochromozytom oder Paragangliom, ECOG 0-2Phäochromozytom, Paragangliom, fortgeschritten oder metastasiertOriginGustave Roussy, Cancer Campus, Grand Paris, FIRSTMAPP trialSt. Marianna University School of Medicine Yokohama City Seibu Hospital, Yokohama, Kanagawa, JapanThe University of Texas MD Anderson Cancer Center, Houston, USA, Natalie TrialUniversity of Texas M.D. Anderson Cancer Center, Houston, LITESPARK-015 trialProtocols in Revision 4 protocols foundBelzutifan 120, Pheochromocytoma / Paraganglioma (PID3094 V1.0)Cabozantinib 60, Pheochromocytoma / Paraganglioma (PID2624 V1.1)CVD - Cyclophosphamide 750 / Vincristine 2 / Dacarbazine 600, Pheochromocytoma / Paraganglioma (PID2480 V1.0)Sunitinib 37.5, Pheochromocytoma / Paraganglioma (PID2485 V1.0)
